Recurrence analysis has emerged as a pivotal framework for understanding the intricate behaviour of complex dynamical systems. By constructing visual representations known as recurrence plots, ...
Thanks to modern, multimodal breast cancer therapies, 5-year local recurrence rates following lumpectomy have dropped significantly, making breast-conserving surgery (BCS) an option for more patients ...
The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its ...
The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...
The Young Women's Breast Cancer Study is a prospective cohort of women diagnosed with breast cancer at age ≤ 40 years and enrolled patients between 2006 and 2016 (N = 1,302). We identified patients ...
Do patients with breast cancer with a low 21-gene recurrence score need regional node irradiation to reduce their risk of locoregional recurrence? Analysis of RxPONDER data suggests only a randomized ...
In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.
Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...
Detailed price information for Greenwich Lifesciences Inc (GLSI-Q) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback